The Pericapsular Nerve Block in Total Hip Arthroplasty

Description

In order to continue progressing towards outpatient total hip arthroplasty (THA), methods to adequately manage postoperative pain is of paramount importance. The purpose of this study is to quantify the effectiveness of the pericapsular nerve block in total hip arthroplasty in comparison to the fascia iliaca nerve block.

Conditions

Hip Osteoarthritis, Hip Arthropathy

Study Overview

Study Details

Study overview

In order to continue progressing towards outpatient total hip arthroplasty (THA), methods to adequately manage postoperative pain is of paramount importance. The purpose of this study is to quantify the effectiveness of the pericapsular nerve block in total hip arthroplasty in comparison to the fascia iliaca nerve block.

The Pericapsular Nerve Block in Total Hip Arthroplasty: a Randomized, Controlled Trial

The Pericapsular Nerve Block in Total Hip Arthroplasty

Condition
Hip Osteoarthritis
Intervention / Treatment

-

Contacts and Locations

Baltimore

Sinai Hospital of Baltimore, Baltimore, Maryland, United States, 21215

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Provision of signed and dated informed consent form
  • * Stated willingness to comply with all study procedures and availability for the duration of the study
  • * Planned primary total hip arthroplasty with anterior (Smith-Peterson) approach
  • * ASA score of 1 to 3
  • * Indicated for one of the two nerve block groups
  • * Must be opioid naïve at screening as defined by the FDA - According to the Food and Drug Administration, opioid-tolerant patients were those currently receiving or who had previously received 60 mg PO morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg PO oxycodone per day, 8 mg PO hydromorphone per day, 25 mg PO oxymorphone per day, 60 mg PO hydrocodone per day, or an equivalent dose of another opioid for a duration of one week or longer (16)
  • * Current or previous diagnosis of "chronic pain"
  • * Opioid tolerant at time of screening (for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid.)
  • * Diagnosis of ankylosing spondylitis
  • * Allergy to any potential medications utilized in any of the two groups
  • * Conversion of patient to general anesthesia intraoperatively
  • * Treatment with another investigational drug or other intervention for pain
  • * Any condition(s) or diagnosis, both physical or psychological, or physical exam finding in the opinion of the investigator that would precludes participation

Ages Eligible for Study

18 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

LifeBridge Health,

Ronald Delanois, MD, PRINCIPAL_INVESTIGATOR, LifeBridge Health

Study Record Dates

2025-12-01